Member Info for Paul2566

I already hold 4663 shares of this stock at an average of £3.0149.
That means I'm down on paper by 6.83%.
I'm keeping an eye on this today and may buy another £5k worth, it just looks cheap, but I need to look at the figures some more in case I'm missing something.

Will we see these prices again.
I'm afraid I'm turning bullish on this stock, and looking at the macroaxis website valuation and stock prediction on any timeframe upto 2 years, it would seem they agree.
I hope both I and macroaxis are proven wrong, but it looks ever likly that I'm going to have to take a hit on this one sooner or later.

So said Canute.

Thanks Android101 & danielh.

I didn't know that, it makes sense now.

I am confused, the article appears to relate to Vodafone PLC (NASDAQ:VOD)
Vodafone (LSE:VOD) has a SP of around £1.09 ($1.50), not $15.9.

Lets hope they exceed their market share then.
Last FY;
Sales = Aus$ 2.96m
Profit from sales after costs = Aus$ 1.31m
Total loss = Aus$ 15.74m

Over 4 years;
By my calcs to hit $15.74m from $1.31 would mean a CAGR of 231%
Of course economies of scale would mean profits after sales in relation to profit from sales would increase dramatically.
Ignoring the cost of sales entirely by my calcs to hit $15.74 from $2.96m would need a CAGR of 51.85%.

Even that seems quite high by my simplistic calculations, but I think its going to take more than a CAGR of 15.3%.

For the FY ending 30th June only 12,457 units of MXC's standardised cannabiniod medicines were sold.
Hopefully this will increase dramatically this FY.

The RNS is the release of a copy of the CimetrATM presentation.

Not really any new information, however reading it I just don't understand why it isn't being more widely used throughout the globe.
It apears to be a cheaper option, reducing the impact on hospitals, and can be self adminstered.

Reduce the relatively high mortality rate that would result from the reduction of professional care, and you are left with a virus that has a reduced impact on the economy that may need little more management than the flu. And we don't generally restrict travel or close borders for the flu.

It just dosen't make sense not to use CimetrATM, unless its less effective than we are led to believe, which I find unlikly. I am certain if that was the case someone would have denounced it by now.

Lets hope you are right.
I think MXC will come good but its not pleasant looking at a 12.61% loss on 405607 shares.
The only real saving grace as someone already posted, is the drop today isn't a result of any poor RNS.
MXC is currently my biggest paper loss by a good margin.

Well there is no real interest from big investors.
The cash runway is getting ever shorter.
Its still not certain the company will reach break even by June 2022.
However its notoriously difficult and expensive for pharma companies to bring products to market.
MCX is moving in the right direction, but its probably going to be a few months before we see 3p + again, but give it a few years and we could be rewarded for our patience.

It feels like there is little to stop it dropping further.
I see the absolute bottom as about 1.8p, but in truth I really can't think it will go below 2.5p.

Another 5% drop.

I too am in the red to the tune of 9.48%.
I thought ULVR would be a safe long term hold.
I think it will pick up at some point, just not for a couple of years.

Yes I'm afraid VOD has not been kind to me.

You got to love a utility stock.

It would appear that this bb is about as active as the ULVR board.

It will get there.
The next 5 years should see decent returns.

I don't really understand whats happening with this, I can't see anything wrong with the stock.
I bought TRIG and UKW in the same month. UKW is up 3.08% and TRIG is down 3.58%.
I was convinced TRIG was the stronger stock of the two.
I will however continue to hold both as I think they will both do well medium to long term.

Well done and good luck to you.
Its one of my defensive stocks, which has served me well. I will continue to hold long term.

I think its more about the market in general rather than SSE, most stocks have been up and down a bit this month.